Thursday, December 5, 2013
Publication and contact
Toll-like receptor 9
(TLR9); signal transducer and activator of transcription 3
Mouse studies suggest
inhibitors of TLR9 or STAT3 could help prevent tumor recurrence after
radiation therapy. In radiation-treated mice bearing melanoma, bladder or
colorectal tumors, Tlr9 knockout decreased activation of Stat3 in
tumor-infiltrating myeloid cells compared with no knockout, thereby
inhibiting tumor revascularization and tumor regrowth. In wild-type mice
bearing those tumor types, radiation and either a TLR9 antagonist or Stat3
small interfering RNA increased the time to tumor regrowth compared with
radiation or targeted therapy alone. Ongoing work includes confirming the
finding in tissue samples from patients with prostate cancer undergoing
Isis Pharmaceuticals Inc.
and AstraZeneca plc have ISIS-STAT3Rx (AZD9150), an antisense
inhibitor of STAT3, in Phase I/II testing to treat solid and blood cancers.
Otsuka Pharmaceutical Co. Ltd.
has OPB-31121, an inhibitor of
STAT3 phosphorylation, in Phase I trials to treat solid tumors.
Dynavax Technologies Corp.
and GlaxoSmithKline plc have DV1179, an inhibitor of
TLR9 and TLR7, in Phase I testing to
treat systemic lupus erythematosus (SLE) and autoimmune and inflammatory
Published online Dec. 5, 2013
Patent application filed by
City of Hope;
available for licensing
Gao, C. et al. Cancer Res.;
published online Oct. 23, 2013;
Contact: Marcin Kortylewski, Beckman Research Institute at
City of Hope, Duarte, Calif.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]